U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177885) titled 'Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans' on Sept. 10.
Brief Summary: Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how ...